返回 Agenda
SESSION 4: WHAT DO TO WITH THE RESULTS OF IMPACT EVALUATIONS – ARE WE READY FOR THE CHANGE?
Session Chair(s)
Gonzalo Calvo Rojas, PHD
Consultant in Clinical Pharmacology
Hospital Clinic Barcelona, Spain
Emma Du Four, MBA
Independent Regulatory and R&D Policy Professional
Independent, United Kingdom
This session will provide the opportunity to discuss amongst all stakeholders the future direction of pharmacovigilance with the aim to focus resources on those activities where impact research provides the required evidence for change.
Speaker(s)
Patient and healthcare professional engagement in impact evaluation of regulatory decision-making
Priya Bahri, PHD, RPH
European Medicines Agency, Netherlands
Senior Lead (Pharmacovigilance and Risk Management Guidance and Policy)
Impact of regulatory risk communication on public health outcomes – challenges and opportunities
Bruce Guthrie
University of Dundee, United Kingdom
NHS Research Scotland Primary Care Research Champion
Outline of a process to identify intended (and unintended) public health outcomes of regulatory decisions
Sue Jordan, PHD
College of Human and Health Sciences, Swansea University, United Kingdom
Professor, Personal research chair, Department of Nursing
Panel Discussion
Rob Camp
EUPATI Spain, Spain
Director, International Patient Collaboration